Paper Details

  1. Home
  2. Paper Details

Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus.

Author: AumaîtreHugues, BlancheStéphane, ChaixMarie-Laure, FirtionGhislaine, FrangePierre, RabaudChristian, ReliquetVéronique, TamaletCatherine, ThuretIsabelle, TricoireJoëlle

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the effectiveness of a combination therapy of raltegravir, r-darunavir, and etravirine in twelve adolescents with multidrug-resistant HIV infection. The combination therapy resulted in a significant decrease in viral load in most patients, with no significant side effects.
Paper Details　
Original Abstract of the Article :
Twelve heavily pretreated, perinatally infected adolescents in virological failure were treated with a combination of raltegravir, r-darunavir and etravirine, as part of an expanded access program in France. After a 12-month median follow-up, viral load was <400 copies/ml in 11 (<50 in six). No grad...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/QAD.0b013e328331a456

データ提供：米国国立医学図書館（NLM）

Fighting Multidrug-Resistant HIV: A New Frontier

The fight against HIV is a constant battle, with the emergence of drug-resistant strains posing significant challenges. This study explores the effectiveness of a combination of raltegravir, etravirine, and r-darunavir in treating multidrug-resistant HIV in adolescents. Researchers investigated the efficacy and safety of this combination in 12 adolescents who had previously failed multiple treatments.

A Promising Treatment for Multidrug-Resistant HIV

The study showed encouraging results, with 11 out of 12 adolescents achieving viral suppression after 12 months of treatment. The combination was well-tolerated, with no serious side effects. This finding offers hope for individuals with multidrug-resistant HIV, suggesting that new treatment strategies are emerging to combat this challenging condition. It's like discovering a new oasis in the desert, offering a source of hope and relief.

The Ongoing Quest for Effective HIV Treatments

This research highlights the ongoing efforts to develop effective treatments for multidrug-resistant HIV. It's a journey that demands continuous research and innovation to address the evolving challenges posed by this complex disease. This study provides a ray of hope, suggesting that new therapies are emerging to combat the threat of drug-resistant HIV.

Dr. Camel's Conclusion

This study explores the effectiveness of a combination of raltegravir, etravirine, and r-darunavir in treating multidrug-resistant HIV in adolescents. The results are promising, offering hope for individuals struggling with this challenging condition. It's like finding a new oasis in the desert, providing a source of hope and relief. This research underscores the importance of continued research and development of new therapies to combat the evolving threat of drug-resistant HIV.

Date :
  1. Date Completed 2011-01-18
  2. Date Revised 2020-12-09
Further Info :

Pubmed ID

19823069

DOI: Digital Object Identifier

10.1097/QAD.0b013e328331a456

Related Literature

Article Analysis
・Side Effects of etravirine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.